Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials. Expand
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected. Expand
Long-Term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD)
Very early or early onset of bipolar disorder might herald a more severe disease course in terms of chronicity and comorbidity and whether early intervention might modify this risk merits further investigation. Expand
Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
- N. Simon, M. Otto, +7 authors M. Pollack
- Psychology, Medicine
- The American journal of psychiatry
- 1 December 2004
An independent association of comorbid anxiety with greater severity and impairment in bipolar disorder patients was demonstrated, highlighting the need for greater clinical attention to anxiety in this population, particularly for enhanced clinical monitoring of suicidality. Expand
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant, suggesting any one of the medications in the study provided a reasonable second-step choice for patients with depression. Expand
Medication augmentation after the failure of SSRIs for depression.
Augmentation of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual clinical settings, including a greater reduction in the number and severity of symptoms and fewer side effects and adverse events. Expand
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
The primary outcome is the clinician-rated, 17-item Hamilton Rating Scale for Depression, administered at entry and exit from each treatment level through telephone interviews by assessors masked to treatment assignments. Expand
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
- G. Sachs, A. Nierenberg, +17 authors M. Thase
- The New England journal of medicine
- 26 April 2007
The use of adjunctive, standard antidepressant medication, as compared with the use of mood stabilizers, was not associated with increased efficacy or with increased risk of treatment-emergent affective switch. Expand
Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD)
The methodology used for the selection and certification of the clinical treatment centers, training study personnel, the general approach to clinical management, and the sequential treatment strategies offered in the STEP-BD standard and randomized care pathways for bipolar depression and relapse prevention are reviewed. Expand
Telomere Shortening and Mood Disorders: Preliminary Support for a Chronic Stress Model of Accelerated Aging
- N. Simon, J. Smoller, +6 authors Kwok-Kin Wong
- Medicine, Psychology
- Biological Psychiatry
- 1 September 2006
Preliminary evidence that mood disorders are associated with accelerated aging is provided and a novel mechanism for mood disorder-associated morbidity and mortality is suggested. Expand